Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium 225 PNT 2001 - POINT Biopharma

Next Previous
X
Search
Drug Profile

Actinium 225 PNT 2001 - POINT Biopharma

Alternative Names: 225Ac-PSMA-62; 225Ac-PSMA-62 PNT2001; 225AC-PNT2001; PNT-2001 actinium 225 isotope

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scintomics
  • Developer POINT Biopharma
  • Class Amides; Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 26 Mar 2024 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in Canada (IV, Injection) (NCT06229366)
  • 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
  • 14 Aug 2023 POINT Biopharma plans a phase I/II trial for Prostate cancer in USA, first quarter of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top